GLP-1 is locally produced in taste bud cells and specifically involved in sweet taste perception, suggesting that GLP-1 drugs may change food preferences partly by directly modulating taste signaling on the tongue.
GLP-1 made in taste budsGLP-1 is locally synthesized in taste bud cells with receptors on adjacent gustatory nerves — a direct taste-modulation circuit specific to sweet perception
What the researchers found
The review establishes several key connections between GLP-1 and taste:
1. GLP-1 is locally synthesized in taste bud cells on the tongue (preclinical evidence)
2. GLP-1 receptors (GLP-1R) are present on gustatory nerves in close proximity to GLP-1-containing taste bud cells
3. GLP-1 signaling is specifically involved in the perception of sweet taste
4. Aging, diabetes, and obesity are all associated with diminished taste and sweet perception
5. Calorie restriction and bariatric surgery reduce appreciation of sweet foods
6. GLP-1 receptor agonists modulate food preference in clinical use
7. Whether GLP-1 drugs directly affect tongue-based taste signaling in humans is currently unknown — the tongue has not been investigated as a clinically relevant target for GLP-1 therapies
Why it matters
One of the most commonly reported effects of GLP-1 drugs is changed food preferences — patients say certain foods, especially sweet and fatty ones, become less appealing. This is widely attributed to brain-mediated appetite suppression, but if GLP-1 drugs also change how food actually tastes at the tongue level, it represents a fundamentally different mechanism. Understanding this could help optimize GLP-1 therapies for maximum appetite control and explain why some patients' food preferences change dramatically while others' do not.
The numbers in context
GLP-1 in taste bud cells; GLP-1R on gustatory nerves; sweet-specific; aging/diabetes/obesity reduce taste; GLP-1 drugs modulate food preference
How the study worked
Systematic review using PubMed, Medline, and Embase databases. The Population-Intervention-Comparison-Outcome (PICO) framework was used to identify interventional studies. The review covered preclinical studies of GLP-1 in taste bud biology, clinical data on taste changes in aging/diabetes/obesity, and evidence on food preference modulation by GLP-1 receptor agonists.
Who was studied
Review covering preclinical taste bud studies and clinical GLP-1 drug effects on food preference
What this study cannot tell us
Most evidence for GLP-1's role in taste perception comes from preclinical (animal) studies. Whether therapeutic doses of GLP-1 drugs reach taste bud cells in the human tongue is unknown. The food preference changes seen clinically could be entirely brain-mediated through reward circuit modulation rather than peripheral taste changes. No interventional human studies have specifically measured taste perception changes in response to GLP-1 drug treatment. The review cannot establish whether the tongue or the brain is the primary site of GLP-1's food preference effects.
How to read the evidence
This systematic review synthesizes mostly preclinical evidence for GLP-1's role in taste biology with clinical observations about food preference changes. The underlying evidence ranges from strong (GLP-1R expression in taste tissue) to speculative (whether GLP-1 drugs affect human taste). Overall evidence is low for the clinical hypothesis but compelling for the biological plausibility.
When this study was published
Published in 2021, this review preceded the massive expansion of GLP-1 drug use. The widespread anecdotal reports of taste changes from millions of semaglutide users have since made this research question even more pressing.
The bigger picture
This review connects two usually separate research fields — taste biology and incretin pharmacology — in a way that could reshape understanding of how GLP-1 drugs work. The food preference changes reported by millions of GLP-1 drug users have been treated as a brain phenomenon, but if the tongue is also involved, it suggests a peripheral sensory mechanism that complements central appetite suppression. This dual-action model (brain + tongue) could explain the remarkable effectiveness of these drugs at changing eating behavior.
Questions still open
- Do GLP-1 drugs reach taste bud cells at sufficient concentrations to modulate sweet taste perception directly?
- Could measuring taste sensitivity before and during GLP-1 treatment predict which patients will experience the strongest food preference changes?
- Would formulations that enhance GLP-1 drug exposure to the tongue (like sublingual delivery) produce greater food preference changes?
Common questions
Why do foods taste different when taking drugs like Ozempic?
Is it normal for sweet foods to taste less appealing on GLP-1 drugs?
Read the original research
Glucagon-like peptide-1, a matter of taste?
Reviews in endocrine & metabolic disorders, 22(4), 763-775
Citation
Jensterle, Mojca; DeVries, J Hans; Battelino, Tadej; Battelino, Saba; Yildiz, Bulent; Janez, Andrej. (2021). Glucagon-like peptide-1, a matter of taste?. Reviews in endocrine & metabolic disorders, 22(4), 763-775. https://doi.org/10.1007/s11154-020-09609-x